Linked Life Data

19188155

Source:http://linkedlifedata.com/resource/pubmed/id/19188155

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-2-3
pubmed:abstractText
Follicular lymphoma (FL) is the most common subtype of indolent lymphomas. Rituximab is widely used alone or in combination therapy for the treatment of FL. Despite its well-established clinical efficacy, a subpopulation of patients does not respond to rituximab and most patients will relapse after therapy. The mechanisms of action and resistance to rituximab are not fully understood.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
851-7
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
In vivo model of follicular lymphoma resistant to rituximab.
pubmed:affiliation
Université Claude Bernard de Lyon, Institut National de la Sante et de la Recherche Medicale, U590, Laboratoire de Cytologie Analytique, Faculte de Medecine Rockefeller, Lyon, France. stephane.dalle@chu-lyon.fr
pubmed:publicationType
Journal Article